Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
It is very uncertain whether COMPARISON 1. ARIPIPRAZOLE changes adverse effects: extrapyramidal effects compared with CLOZAPINE (very low certainty).
1 finding from 1 review
General functioning ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia
COMPARISON 2. ARIPIPRAZOLE showed no clear difference in global state: No clinically significant response (as defined by… compared with QUETIAPINE (low certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · patients with schizophrenia
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · schizophrenia
1 finding from 1 review
Quality of life: substantial improvement · schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · schizophrenia
QUETIAPINE probably leads to lower adverse effects: 1. Sedation compared with CLOZAPINE ‐ all data short term (moderate certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia
1 finding from 1 review
Weight gain · schizophrenia
QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain compared with CLOZAPINE ‐ all data short term (low certainty).
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia
1 finding from 1 review
Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · schizophrenia
1 finding from 1 review
Quality of life (medium term: 12 months) · schizophrenia
1 finding from 1 review
Adverse effects: 1. Sedation · schizophrenia
QUETIAPINE showed no clear difference in adverse effects: 1. Sedation compared with OLANZAPINE (moderate certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia
1 finding from 1 review
Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia
1 finding from 1 review
Adverse effects: 3. Metabolic ‐ weight significant gain · schizophrenia
QUETIAPINE probably leads to lower adverse effects: 3. Metabolic ‐ weight significant gain compared with OLANZAPINE (moderate certainty).
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review